

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Microwave-assisted synthesis of novel purine nucleosides as selective cholinesterase inhibitors

S. Schwarz,^{a,b} R. Csuk^b and A. P. Rauter^{a,*}

Alzheimer's disease (AD), the most common form of senile dementia, is characterized by high butyrylcholinesterase (BChE) levels in the brain in later AD stages, for which no treatment is available. Pursuing our studies on selective BChE inhibitors, that may contribute to understand the role of this enzyme in disease progression, we present now microwave-assisted synthesis and anticholinesterase activity of a new nucleoside series embodying 6-chloropurine or 2-acetamido-6-chloropurine linked to D-glucosyl, D-galactosyl and D-mannosyl residues. It was designed to assess the contribution of sugar stereochemistry, purine structure and linkage to the sugar for cholinesterase inhibition efficiency and selectivity. Compounds were subjected to Ellman's assay and their inhibition constants determined. The α -anomers were the most active compounds, while selectivity for BChE or acetylcholinesterase (AChE) inhibition could be tuned by the purine base, by the glycosyl moiety and by N⁷-ligation. Some of the nucleosides were far more potent than the drug galantamine, and the most promising competitive and selective BChE inhibitor, the N⁷-linked 2-acetamido- α -D-mannosylpurine, showed a K_i of 50 nM and a selectivity factor of 340 fold for BChE over AChE.

Received 19th January 2014,

Accepted

Cite this: DOI: 10.1039/x0xx00000x

DOI: 10.1039/x0xx00000x

www.rsc.org/

Introduction

More than 100 years after Alois Alzheimer first described a new neurodegenerative disease¹ that now bears his name, there is still no cure available for it. The Alzheimer's disease (AD) is a multifactorial disease characterized by the presence of β -amyloid plaques and neurofibrillar tangles in the brain and also a decrease of the level of the neurotransmitter acetylcholine (ACh), that causes a dysfunction of the cholinergic activity, which results in a decline in memory and recognition.²⁻⁴ The level of acetylcholine in the brain is controlled by the hydrolase acetylcholinesterase (AChE, E.C. 3.1.1.7). Also butyrylcholinesterase (BChE, E.C. 3.1.1.8) is able to hydrolyze ACh, although it does not have the same affinity as AChE.⁵ It is known that about 80% of the cholinergic activity inside human brain is caused by AChE.⁶ However AChE levels decrease in AD, while those of BChE are highly increased. The ratio of

BChE/AChE changes from 0.5 in normal brain to 11 in AD brain⁷ but the reduced AChE activity may be upregulated by BChE,^{8,9} whose activity is doubled in advanced AD.^{10,11} Current treatment of AD is based on the AChE inhibitors galantamine¹² and donepezil^{13,14} and the dual cholinesterase inhibitor rivastigmine¹⁵ that raise ACh level and improve cognitive abilities.^{16,17} However these drugs are only effective in the early stages of disease.

Histochemical analysis of Alzheimer disease (AD) brain tissues indicates that BChE is also present in β -amyloid (A β) plaques and recent studies in transgenic mouse model of AD suggested that it may play a role in AD plaque maturation.¹⁸ Currently under investigation,¹⁹ the influence of BChE on AD pathology is still unclear.

Selective BChE inhibitors will facilitate a better understanding of the role of this enzyme on AD progression. One of the first successful attempts to obtain selective BChE inhibitors was accomplished by Creig *et al.* investigating derivatives of cymserin,⁷

followed by Takahashi describing norecymserin derivatives.²⁰ Other groups succeeded by dealing with derivatives of polyphenol²¹ and quinazolinimine.²² The use of purine nucleotides appeared to be promising and cycloSal pronucleotides showed selectivity towards inhibition of BChE.^{23,24} More recently Marcelo *et al.* synthesized a series of highly active purine nucleosides.²⁵ Those compounds, bearing a benzyl protected bicyclic sugar moiety N⁷ and β -linked to 2-acetamido-6-chloropurine, exhibited BChE selectivity and one of them showed nM inhibition of the same order of magnitude as that of rivastigmine. These results encouraged us to launch our investigation into the impact of the sugar and purine structure on this new family of selective BChE inhibitors. Therefore, a series of benzylated glycosyl donors with D-*gluco*, D-*manno* and D-*galacto* configuration were linked either to 6-chloropurine (CP) or 2-acetamido-6-chloropurine (ACP). The reaction conditions of Marcelo *et al.*²⁵ were optimized for this family of compounds and microwave-assisted reactions were carried out for the glycosylation reaction. The inhibitory activities of all compounds were determined by Ellman's assays using AChE and BChE aiming to find efficient and selective BChE inhibitors of simplified structure when compared to the parent nucleosides previously described by our group.²⁵

Results and discussion

Chemistry. 6-Chloropurine nucleoside synthesis has been described starting from 1-*O*-acetyl glycosyl donors and mediated by stannic chloride in acetonitrile to give N⁹-regioselectivity with the ribofuranosyl donor²⁶ and N⁷-regioselectivity with the glucosyl donor.²⁶ Alternatively, TMSOTf mediated reaction gave the product resulting from thermodynamic control, the N⁹-regioisomer.^{27,28} Furthermore, the direct coupling of a persilylated purine with a methyl furanoside using Lewis acid activation of the anomeric centre by stannic chloride³⁰ or by TMSOTf³¹ has been accomplished. Also a furanosyl halide has been activated by stannic chloride to give a purine nucleoside.²⁹ Other leaving groups have also been used, namely the phenylsulfanyl group activated by *N*-iodosuccinimide/triflic acid to yield the N⁹-regioisomer.²⁷ Marcelo *et al.* applied TMSOTf in acetonitrile for the first time to couple methyl bicyclic hexosides to a purine scaffold with β -stereoselectivity and N⁷-regioselectivity in 58–65% yield.²⁵ Hence, we started from the perbenzylated methyl glycoside precursors and investigated their conjugation with persilylated CP as well as ACP. The influence of the concentration of activating TMSOTf as well as that of microwave irradiation onto yield and reaction stereo- and regioselectivity were studied. Four products were formed that differed in their anomeric configuration and linkage of the glycosyl group to purine either in N⁷- or N⁹-position (Table 1). For CP glucosylation the ratio α/β is in favor of the β -anomer for both regioisomers, but the β -selectivity for the N⁷-isomer increased with the concentration of the activator. In ACP glucosylation the same trends were observed but N⁹-selectivity detected for CP glucosylation did not occur.

When using microwave irradiation instead of conventional heating, the time for glucosylation completion of CP and ACP dropped significantly from 2 h to 15 min but reaction regioselectivity and stereoselectivity were not significantly altered. Consequently, all compounds were further synthesized by microwave-assisted synthesis.

The anomeric configuration as well as the substitution at N⁷ or N⁹ of the compounds was determined from their ¹H- and ¹³C NMR spectra, COSY, HMQC, HMBC and gHSQC experiments. The chemical shift of purine carbon 5 can be used to distinguish between N⁷- and N⁹-substitution.

Table 1. Conditions for the reaction of methyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucoside with the purines CP or ACP^a


Purine	TMSOTf (eq.)	Time	N ⁷ /N ⁹	N ⁷ α/β	N ⁹ α/β	Total yield
CP	2	2 h	1/1.4	1/1.7	1/6.0	56 %
CP	4	2 h	1/3.8	1/2.6	1/5.8	75 %
CP	8	2 h	1/3.4	1/3.6	1/5.9	78 %
CP	8	15 min (mw)	1/2.5	1/2.2	1/4.6	81 %
ACP	2	2 h	1/1.4	1.1/1	1/4.0	2 %
ACP	4	2 h	1.3/1	1/2.2	1/8.5	80 %
ACP	8	2 h	1/1.2	1/6.2	1/8.2	71 %
ACP	8	15 min (mw)	1.3/1	1/5.0	1/9.3	74 %

^a Yields and product ratios were determined by ¹H NMR experiments; 1 equivalent of the monosaccharide and 1.5 equivalents of the silylated purine in dry acetonitrile were used under conventional heating or microwave-assisted heating (mw) at 65°C. No product was formed with both purines in the presence of 1 equivalent of TMSOTf.

It was found to be about $\delta = 122$ ppm for N⁷ CP and about $\delta = 118$ ppm for N⁷ ACP, while substitution at N⁹ resulted in chemical shifts of about $\delta = 131$ ppm for CP and about $\delta = 128$ ppm for ACP derivatives. The anomeric configuration was unambiguously assigned from the coupling constant ³J_{1,2} and the chemical shift of H-1 of the glycosyl group. For D-*gluco* or D-*galacto* configured products the coupling constants ³J_{1,2} = 5 Hz (for glucosyl group) and ³J_{1,2} = 3 Hz (for galactosyl group) confirm the α -configuration with H-1 chemical shifts observed between $\delta = 6.1$ and $\delta = 6.4$ ppm. The corresponding β -anomers presented H-1 chemical shifts between $\delta = 5.4$ and $\delta = 5.7$ ppm and coupling constants ³J_{1,2} ranging from 7 to 9 Hz, characteristic of the trans-diaxial position of H-1 and H-2. For D-*manno* configured compounds coupling constants ³J_{1,2} of approx. $J = 9$ Hz for the α -anomers and 1 Hz for the β -anomers were obtained.

In the ¹³C NMR spectra, chemical shifts of $\delta = 79$ to $\delta = 81$ ppm for the α -anomers and of $\delta = 83$ to $\delta = 85$ ppm for the β -anomers were found in excellent agreement with those previously reported for related nucleosides.²⁵

The highest β/α ratio (9:1) was found in the glucosylation of 2-acetamido-6-chloropurine, while galactosylation of 6-chloropurine afforded the highest β/α ratio (8:1). N⁹-regioselectivity was observed for the chloropurine nucleosides bearing galactosyl or glucosyl residues while introduction of the substituent 2-acetamido favours N⁷-linked nucleosides leading to N⁹/N⁷ ratio ca. 1.0. However, the N⁷-linked D-*manno* nucleosides bearing the 2-acetamido-6-chloropurine exhibit a β/α ratio (3.5:1) while for the 6-chloropurine no selectivity occurs. With both the purine bases, α -selectivity is found for the N⁹-linked nucleosides.



Scheme 1. Reagents and conditions: (a) Silylated CP or ACP, TMSOTf, acetonitrile, microwave irradiation (150 W), 65°C, 15 min.

Biology. All compounds were subjected to Elman's assay varying substrate and compound concentration to evaluate the inhibition constants K_i (dissociation constant of enzyme-inhibitor complex in competitive inhibition) and K_i' (dissociation constant of enzyme-substrate-inhibitor complex in non-competitive inhibition) and the type of inhibition caused by the 24 synthesized nucleosides. The data for the compounds, for their parent purines and for galantamine hydrobromide - a common drug used for treating Alzheimer's - are compiled in Table 2. Since the glycosyl residues carry four benzyl groups, with the exception of compounds **1** and **2**, the solubility was poor under the assay conditions. Thus, for some of the compounds specific data could not be obtained. For these compounds the maximum compound concentration was too low to cause a detectable inhibition, although the cut-off of our assay (100 μM) was not reached. Hence, it was not possible to receive enough data for a definite statement of structure-activity relationship studies for all the compounds tested. Nevertheless, some structural principles as well as tendencies could be determined. First of all, most of the compounds showed a competitive inhibition on both cholinesterases as galantamine hydrobromide did. Galantamine hydrobromide has shown a higher impact on AChE than on BChE. The selectivity factor of galantamine, given by the quotient of K_i (AChE) and K_i (BChE), is 0.06. The unsubstituted purines CP and ACP showed no inhibition on BChE at all, but a linear mixed type inhibition on AChE. This allowed to determine their selectivity for AChE inhibition. The *D-gluco* and *D-galacto* chloropurine nucleosides were selective for AChE inhibition, with the exclusion of both the perbenzylated N⁷- β -nucleosides that could not be evaluated due to their poor solubility under the assay conditions. In addition, N⁷- or

N⁹-ligation does not seem to be crucial for AChE selective inhibition of chloropurine nucleosides, also including those of the *D-manno* series.

Table 2. Inhibitory constant K_i for nucleosides **1-24** as determined by Elman's assay with BChE and AChE in comparison to galantamine hydrobromide.^a

				K_i (μM) (BChE)	K_i (μM) (AChE)
Galantamine hydrobromide				9.4 ± 0.7	0.5 ± 0.0
6-Chloropurine (CP)				> 100	55.5 ± 3.9 ^c
2-Acetamido-6-chloropurine (ACP)				> 100	26.1 ± 2.8 ^d
1	CP	N ⁷	β	> 100	28.9 ± 2.1
2	CP	N ⁹	β	> 100	17.5 ± 2.6 ^e
3	CP	N ⁷	α	> 20	9.6 ± 2.3
4	CP	N ⁷	β	> 2	> 2
5	CP	N ⁹	α	> 100	17.0 ± 2.0
6	CP	N ⁹	β	> 100	16.0 ± 2.7 ^f
7	CP	N ⁷	β	> 20	> 20
8	CP	N ⁹	α	> 10	5.6 ± 0.8
9	CP	N ⁹	β	> 100	25.6 ± 2.1
10	CP	N ⁷	α	30.9 ± 2.2	23.4 ± 3.6
11	CP	N ⁷	β	9.6 ± 0.7	28.5 ± 6.5
12	CP	N ⁹	α	2.8 ± 0.3	2.4 ± 0.3
13	CP	N ⁹	β	> 20	> 20
14	ACP	N ⁷	α	2.5 ± 0.3	> 10
15	ACP	N ⁷	β	> 100	23.0 ± 1.9
16	ACP	N ⁹	β	> 2	> 2
17	ACP	N ⁷	α	50.0 ± 7.0	42.0 ± 9.2
18	ACP	N ⁷	β	> 20	> 20
19	ACP	N ⁹	α	> 2	> 2
20	ACP	N ⁹	β	> 2	> 2
21	ACP	N ⁷	α	0.05 ± 0.01^b	18.1 ± 4.8
22	ACP	N ⁷	β	1.4 ± 0.1	3.0 ± 0.3
23	ACP	N ⁹	α	10.3 ± 2.6	17.1 ± 2.5
24	ACP	N ⁹	β	> 10	> 10

^a Four different substrate concentrations and 4 different inhibitor concentrations were used. Each experiment was performed in triplicate. Poor compound solubility limited the evaluation of K_i when lying above the given concentration; ^b $K_i' = 0.7 \pm 0.1 \mu\text{M}$; ^c $K_i' = 115.4 \pm 20.5 \mu\text{M}$; ^d $K_i' = 85.8 \pm 10.7 \mu\text{M}$; ^e $K_i' = 74.3 \pm 7.1 \mu\text{M}$; ^f $K_i' = 44.6 \pm 14.3 \mu\text{M}$.

The introduction of the perbenzylated mannosyl substituent increased the inhibitory activity considerably. With the exception of both N⁹- β -diastereomers, inhibitory constants ranging from 50 nM to 30 μM were determined. Noteworthy low inhibition constants were shown by both anomers N⁷-linked to ACP when compared to their N⁷-linked CP counterparts. The α -anomers were in general the most active compounds for the inhibition of both cholinesterases. However selectivity for BChE inhibition was mostly shown by the 2-acetamidochloropurine nucleosides, particularly those which exhibit N⁷-ligation to the α -D-glucosyl or the α -D-mannosyl group, with the exception of compound **11**, the single chloropurine nucleoside that is a BChE selective inhibitor.

Within all 24 compounds studied, compound **21**, bearing a 2-acetamido-6-chloropurine base N⁷-linked to a α -D-mannosyl group, was the most potent BChE inhibitor possessing a K_i of 50 nM. Furthermore, this nucleoside showed an extraordinary selectivity as demonstrated by a selectivity factor of 340.

Experimental

General Experimental Procedures. Reagents were purchased from commercial suppliers without any further purification. Microwave assisted synthesis was performed with a CEM Discover and Explorer SP. Melting points were measured with a Melting Point Apparatus, SMP3, Stuart Scientific, Bibby and were not corrected. NMR spectra were recorded on BRUKER Avance 400 spectrometer at 298 K with trimethylsilane as an internal standard, δ are given in ppm and J in Hz. Mass spectra were taken on a FINNIGAN MAT TSQ 7000 (electrospray, voltage 4.5 kV, sheath gas nitrogen) instrument. Elemental analyses were measured on a Foss-Heraeus Vario EL unit. Optical rotations were determined on a Perkin-Elmer 341 polarimeter. TLC was performed on silica gel (Merck 5554). Solvents were dried before use according to usual procedures. The purity of the compounds was checked by HPLC-DAD and found to be > 95 % for each compound.

N-Glycosylation: General Procedure. *N,O*-Bis(trimethylsilyl)acetamide (BSA) (1.5 eq. for CP and 3.0 eq. for ACP) was added to a mixture of the respective purine (1.5 eq.) in dry acetonitrile. The mixture was stirred at room temperature for 40 min. Then, the corresponding methyl glycoside (1 eq.), dissolved in dry acetonitrile, and trimethylsilyl trifluoromethanesulfonate (TMSOTf) were added. The reaction was performed under microwave irradiation (150 W, 65 °C, 15 min). The mixture was poured into dichloromethane, washed with a saturated solution of Na₂CO₃ and extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with brine, dried (MgSO₄) and concentrated and compounds isolated purified by column chromatography.

6-Chloro-7-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)purine (1) and *6-Chloro-9-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)purine (2)*. The compounds obtained by the reaction of methyl 2,3,4,6-tetra-O-acetyl- α -D-glucopyranoside (70 mg, 0.18 mmol) and CP (44 mg, 0.27 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **1** (17.5 mg; 20 %) and **2** (35.8 mg; 41 %). Data for compound **1**: colourless oil; Rf = 0.35 (EtOAc/hexane, 3:1). $[\alpha]_D^{20} - 12^\circ$ (c 1.03, CHCl₃). ESI-MS m/z (%): 485.0 ([M + H]⁺, 100), 507.3 ([M + Na]⁺, 22), 969.9 ([2M + H]²⁺, 10), 991.0 ([2M + Na]⁺, 16). ¹H NMR (400 MHz, CDCl₃): δ 8.94 (s, 1H, H-2), 8.50 (s, 1H, H-8), 6.18 (d, $J = 8.1$ Hz, 1H, H-1'), 5.69 (dd, $J = 8.9$ Hz, $J = 8.1$ Hz, 1H, H-2'), 5.48 (dd, $J = 9.3$ Hz, $J = 8.8$ Hz, 1H, H-3'), 5.28 (dd, $J = 9.6$ Hz, $J = 9.3$ Hz, 1H, H-4'), 4.28 (dd, $J = 12.5$ Hz, $J = 4.7$ Hz, 1H, H-6'a), 4.18 (d, $J = 12.5$ Hz, 1H, H-6'b), 4.10 (m, 1H, H-5'), 2.08 (s, 6H, 2 × Ac-CH₃), 2.05 (s, 3H, Ac-CH₃), 2.04 (s, 3H, Ac-CH₃). ¹³C NMR (100 MHz, CDCl₃): δ 170.4 (Ac-COO), 169.9 (Ac-COO), 169.2 (Ac-COO), 169.0 (Ac-COO), 162.2 (C-4), 153.1 (C-2), 146.3 (C-8), 142.9 (C-6), 122.2 (C-5), 82.6 (C-1'), 75.0 (C-5'), 72.9 (C-3'), 69.8 (C-2'), 67.5 (C-4'), 61.4 (C-6'), 20.6 (Ac-CH₃), 20.5 (Ac-CH₃), 20.5 (Ac-CH₃), 20.2 (Ac-CH₃). Elemental anal. calcd for C₁₉H₂₁ClN₄O₉: C, 47.07; H, 4.37; N, 11.56; Found: C, 46.86; H, 4.50; N, 11.31.

Data for compound **2**: colourless crystals; mp 175-179 °C; Rf = 0.69 (EtOAc/hexane, 3:1). $[\alpha]_D^{20} - 15^\circ$ (c 1.08, CHCl₃). ESI-MS m/z (%): 485.1 ([M+H]⁺, 100), 507.4 ([M + Na]⁺, 30), 969.8 ([2M + H]²⁺, 8), 991.3 ([2M + Na]⁺, 18). ¹H NMR (400 MHz, CDCl₃): δ 8.79 (s, 1H,

H-2), 8.32 (s, 1H, H-8), 5.95 (d, $J = 9.4$ Hz, 1H, H-1'), 5.67 (dd, $J = 9.4$ Hz, $J = 9.4$ Hz, 1H, H-2'), 5.48 (dd, $J = 9.4$ Hz, $J = 9.4$ Hz, 1H, H-3'), 5.31 (dd, $J = 9.6$ Hz, $J = 9.4$ Hz, 1H, H-4'), 4.30 (dd, $J = 12.7$ Hz, $J = 4.7$ Hz, 1H, H-6'a), 4.16 (d, $J = 12.7$ Hz, 1H, H-6'b), 4.05 (m, 1H, H-5'), 2.08 (s, 3H, Ac-CH₃), 2.07 (s, 3H, Ac-CH₃), 2.04 (s, 3H, Ac-CH₃), 1.78 (s, 3H, Ac-CH₃). ¹³C NMR (100 MHz, CDCl₃): δ 170.4 (Ac-COO), 169.9 (Ac-COO), 169.3 (Ac-COO), 168.9 (Ac-COO), 152.5 (C-2), 151.7 (C-4), 151.6 (C-6), 142.9 (C-8), 131.5 (C-5), 80.8 (C-1'), 75.2 (C-5'), 72.7 (C-3'), 70.1 (C-2'), 67.6 (C-4'), 61.4 (C-6'), 20.7 (Ac-CH₃), 20.5 (Ac-CH₃), 20.5 (Ac-CH₃), 20.1 (Ac-CH₃). Elemental anal. calcd for C₁₉H₂₁ClN₄O₉: C, 47.07; H, 4.37; N, 11.56; Found: C, 46.93; H, 4.47; N, 11.47.

6-Chloro-7-(2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)purine (3), *6-Chloro-7-(2,3,4,6-tetra-O-benzyl- β -D-glucopyranosyl)purine (4)*, *6-Chloro-9-(2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)purine (5)* and *6-Chloro-9-(2,3,4,6-tetra-O-benzyl- β -D-glucopyranosyl)purine (6)*. The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl- α -D-glucopyranoside (100 mg, 0.18 mmol) and CP (44 mg, 0.27 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **3** (7.3 mg; 6 %), **4** (20.7 mg; 17 %), **5** (12.2 mg; 10 %) and **6** (54.8 mg; 45 %). Data for compound **3**: colourless oil; Rf = 0.27 (EtOAc/hexane 1:2). $[\alpha]_D^{20} - 13^\circ$ (c 0.88, CHCl₃). ESI-MS m/z (%): 676.9 ([M + H]⁺, 100), 699.1 ([M + Na]⁺, 20), 1353.7 ([2M + H]²⁺, 22), 1374.9 ([2M + Na]⁺, 12). ¹H NMR (400 MHz, CDCl₃): δ 8.85 (s, 1H, H-2), 8.70 (s, 1H, H-8), 7.43-7.02 (m, 18H, Bn H), 6.90 (m, 2H, Bn H), 6.35 (d, $J = 4.8$ Hz, 1H, H-1'), 4.85 (d, $J = 11.3$ Hz, 1H, Bn-CHH), 4.80 (d, $J = 11.3$ Hz, 1H, Bn-CHH), 4.75 (d, $J = 11.1$ Hz, 1H, Bn-CHH), 4.70 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.57 (d, $J = 11.1$ Hz, 1H, Bn-CHH), 4.56 (d, $J = 12.2$ Hz, 1H, Bn-CHH), 4.48 (d, $J = 12.2$ Hz, 1H, Bn-CHH), 4.32 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.12 (dd, $J = 6.8$ Hz, $J = 4.8$ Hz, 1H, H-2'), 4.06 (dd, $J = 6.8$ Hz, $J = 6.6$ Hz, 1H, H-3'), 3.86 (dd, $J = 9.1$ Hz, $J = 6.6$ Hz, 1H, H-4'), 3.68-3.64 (m, 2H, H-6'a and H-5'), 3.56 (m, 1H, H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 161.7 (C-4), 152.4 (C-2), 148.7 (C-8), 143.0 (C-6), 137.6 (Bn-Cq), 137.5 (Bn-Cq), 137.4 (Bn-Cq), 136.1 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 121.7 (C-5), 81.0 (C-1'), 80.6 (C-3'), 77.2 (C-2'), 76.5 (C-4'), 74.4 (Bn-CH₂), 74.2 (Bn-CH₂), 73.9 (Bn-CH₂), 73.5 (Bn-CH₂), 73.2 (C-5'), 67.9 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 68.86; H, 5.72; N, 8.12.

Data for compound **4**: colourless oil; Rf = 0.10 (EtOAc/hexane 1:2). $[\alpha]_D^{20} - 9^\circ$ (c 1.01, CHCl₃). ESI-MS m/z (%): 587.1 ([M - Bn + H]⁺, 90), 609.3 ([M - Bn + Na]⁺, 48), 677.0 ([M + H]⁺, 100). ¹H NMR (400 MHz, CDCl₃): δ 8.84 (s, 1H, H-2), 8.23 (s, 1H, H-8), 7.40-7.17 (m, 15H, BnH), 7.07-6.95 (m, 3H, BnH), 6.74 (m, 2H, BnH), 5.72 (br, 1H, H-1'), 5.01 (d, $J = 10.9$ Hz, 1H, Bn-CHH), 4.95 (d, $J = 10.9$ Hz, 1H, Bn-CHH), 4.89 (d, $J = 10.7$ Hz, 1H, Bn-CHH), 4.64 (d, $J = 10.7$ Hz, 1H, Bn-CHH), 4.63 (d, $J = 11.5$ Hz, 1H, Bn-CHH), 4.54 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.48 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.23 (d, $J = 11.5$ Hz, 1H, Bn-CHH), 3.97 (m, 1H, H-2'), 3.95-3.86 (m, 2H, H-3' and H-5'), 3.78-3.70 (m, 3H, H-4' and H-6'a and H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 161.4 (C-4), 152.1 (C-2), 147.0 (C-8), 143.1 (C-6), 137.8 (Bn-Cq), 137.5 (Bn-Cq), 137.5 (Bn-Cq), 135.8 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 122.1 (C-5), 86.0 (C-3'), 85.2 (C-1'), 80.1 (C-2'), 78.1 (C-4'), 77.2 (C-5'), 75.9 (Bn-CH₂), 75.3 (Bn-CH₂), 74.7 (Bn-CH₂), 73.5 (Bn-

CH₂), 68.2 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 68.98; H, 5.42; N, 8.02.

Data for compound **5**: colourless oil; Rf = 0.55 (EtOAc/hexane 1:2). [α]_D²⁰ + 28° (c 1.07, CHCl₃). ESI-MS *m/z* (%): 677.1 ([M + H]⁺, 100), 699.3 ([M + Na]⁺, 16), 1354.8 ([2M + H]⁺, 18). ¹H NMR (400 MHz, CDCl₃): δ 8.67 (s, 1H, H-2), 8.40 (s, 1H, H-8), 7.40-7.08 (m, 18H, BnH), 6.92 (m, 2H, BnH), 6.26 (d, *J* = 4.9 Hz, 1H, H-1'), 4.86 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.80 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.74 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.60 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.54 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.54 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.45 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.32 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.16 (dd, *J* = 7.2 Hz, *J* = 6.0 Hz, 1H, H-3'), 4.12 (dd, *J* = 7.2 Hz, *J* = 4.9 Hz, 1H, H-2'), 3.85 (dd, *J* = 9.4 Hz, *J* = 5.9 Hz, 1H, H-4'), 3.81 (m, 1H, H-5'), 3.70 (dd, *J* = 10.8 Hz, *J* = 3.8 Hz, 1H, H-6'a), 3.59 (dd, *J* = 10.8 Hz, *J* = 2.1 Hz, 1H, H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 152.0 (C-2), 151.6 (C-4), 150.9 (C-6), 144.9 (C-8), 138.1 (Bn-Cq), 137.7 (Bn-Cq), 137.7 (Bn-Cq), 136.3 (Bn-Cq), 131.3 (C-5), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (Bn), 128.3 (Bn), 128.2 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 79.8 (C-3'), 79.4 (C-1'), 76.3 (C-2'), 76.1 (C-4'), 73.6 (C-5'), 74.1 (Bn-CH₂), 74.0 (Bn-CH₂), 73.5 (Bn-CH₂), 73.2 (Bn-CH₂), 67.9 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 68.84; H, 5.70; N, 8.03.

Data for compound **6**: colourless crystals; mp 146-149 °C; Rf = 0.35 (EtOAc/hexane 1:2). [α]_D²⁰ - 24° (c 1.03, CHCl₃). ESI-MS *m/z* (%): 677.1 ([M + H]⁺, 100), 699.3 ([M + Na]⁺, 29), 1354.7 ([2M + H]⁺, 12). ¹H NMR (400 MHz, CDCl₃): δ 8.68 (s, 1H, H-2), 8.03 (s, 1H, H-8), 7.39-7.27 (m, 13H, BnH), 7.23-7.18 (m, 2H, BnH), 7.12 (m, 1H, BnH), 6.99 (m, 2H, BnH), 5.59 (d, *J* = 9.0 Hz, 1H, H-1'), 4.99 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.94 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.88 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.65 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.61 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.55 (d, *J* = 12.2 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 12.2 Hz, 1H, Bn-CHH), 4.17 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.07 (dd, *J* = 9.0 Hz, *J* = 9.0 Hz, 1H, H-2'), 3.91 (dd, *J* = 9.0 Hz, *J* = 8.3 Hz, 1H, H-3'), 3.87 (dd, *J* = 9.6 Hz, *J* = 9.1 Hz, 1H, H-4'), 3.77-3.68 (m, 3H, H-6'a and H-5' and H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 152.0 (C-2), 151.4 (C-4), 151.0 (C-6), 143.2 (C-8), 137.9 (Bn-Cq), 137.7 (Bn-Cq), 137.6 (Bn-Cq), 136.2 (Bn-Cq), 131.5 (C-5), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.1 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 85.9 (C-3'), 83.3 (C-1'), 79.9 (C-2'), 78.3 (C-5'), 77.2 (C-4'), 75.9 (Bn-CH₂), 75.3 (Bn-CH₂), 74.9 (Bn-CH₂), 73.5 (Bn-CH₂), 68.2 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.02; H, 5.38; N, 8.11.

6-Chloro-7-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)purine (7), *6-Chloro-9-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)purine (8)* and *6-Chloro-9-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)purine (9)*. The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranoside (120 mg, 0.21 mmol) and CP (49 mg, 0.32 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **7** (17 mg; 12 %), **8** (9.9 mg; 7 %) and **9** (60.9 mg; 43 %). Data for **7**: colourless oil; Rf = 0.30 (EtOAc/hexane 1:1). [α]_D²⁰ - 22° (c 1.00, CHCl₃). ESI-MS *m/z* (%): 587.0 ([M - Bn + H]⁺, 100), 609.3 ([M - Bn + Na]⁺, 70), 676.9 ([M + H]⁺, 7). ¹H NMR (400 MHz, CDCl₃): δ 8.83 (s, 1H, H-2), 8.26 (s, 1H, H-8), 7.44-7.23 (m, 15H, BnH), 7.11-6.96 (m, 3H, BnH), 6.75 (m, 2H, BnH), 5.78 (d, *J* = 8.1 Hz, 1H, H-1'), 5.01 (d, *J* = 11.2 Hz, 1H, Bn-CHH), 4.85 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.78 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.70 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.36 (d, *J* =

11.2 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.43 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.28 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.29 (m, 1H, H-2'), 4.10 (dd, *J* = 1.9 Hz, *J* = 1.9 Hz, 1H, H-4'), 3.86 (dd, *J* = 6.3 Hz, *J* = 6.3 Hz, 1H, H-5'), 3.81 (dd, *J* = 9.4 Hz, *J* = 2.5 Hz, 1H, H-3'), 3.66-3.58 (m, 2H, H-6'a and H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 161.6 (C-4), 152.1 (C-2), 147.2 (C-8), 143.2 (C-6), 138.2 (Bn-Cq), 137.5 (Bn-Cq), 137.4 (Bn-Cq), 136.2 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.2 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.6 (Bn), 127.6 (Bn), 122.3 (C-5), 85.2 (C-1'), 83.4 (C-3'), 77.2 (C-2'), 76.6 (C-5'), 75.0 (Bn-CH₂), 74.9 (Bn-CH₂), 73.6 (Bn-CH₂), 73.1 (C-4), 72.6 (Bn-CH₂), 68.2 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 68.97; H, 5.69; N, 7.99.

Data for compound **8**: colourless oil; Rf = 0.43 (EtOAc/hexane 1:2). [α]_D²⁰ - 14° (c 1.00, CHCl₃). ESI-MS *m/z* (%): 587.0 ([M - Bn + H]⁺, 72), 609.3 ([M - Bn + Na]⁺, 62), 677.0 ([M + H]⁺, 100), 1354.8 ([2M + H]⁺, 29). ¹H NMR (400 MHz, CDCl₃): δ 8.65 (s, 1H, H-2), 8.38 (s, 1H, H-8), 7.44-7.28 (m, 14H, BnH), 7.18-7.09 (m, 4H, BnH), 6.85 (m, 2H, BnH), 6.29 (d, *J* = 3.0 Hz, 1H, H-1'), 4.82 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.71 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.69 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.64 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.53 (d, *J* = 14.4 Hz, 1H, Bn-CHH), 4.51 (d, *J* = 14.4 Hz, 1H, Bn-CHH), 4.41 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.39 (m, 1H, H-5'), 4.21 (dd, *J* = 4.9 Hz, *J* = 2.9 Hz, 1H, H-4'), 4.13 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.09-4.06 (m, 2H, H-6'a and H-3'), 3.93 (dd, *J* = 5.5 Hz, *J* = 3.1 Hz, 1H, H-2'), 3.82 (dd, *J* = 11.3 Hz, *J* = 3.8 Hz, 1H, H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 151.6 (C-2), 150.8 (C-4), 150.5 (C-6), 145.2 (C-8), 137.8 (Bn-Cq), 137.8 (Bn-Cq), 137.6 (Bn-Cq), 136.0 (Bn-Cq), 131.1 (C-5), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.3 (Bn), 128.3 (Bn), 128.2 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.6 (Bn), 77.2 (C-1'), 75.5 (C-5'), 74.4 (C-2'), 74.4 (C-3'), 73.4 (Bn-CH₂), 73.3 (Bn-CH₂), 73.2 (Bn-CH₂), 72.8 (Bn-CH₂), 72.6 (C-4'), 65.8 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.13; H, 5.59; N, 8.13.

Data for compound **9**: colourless oil; Rf = 0.30 (EtOAc/hexane 1:2). [α]_D²⁰ - 16° (c 0.92, CHCl₃). ESI-MS *m/z* (%): 497.1 ([M - 2Bn + H]⁺, 8), 519.3 ([M - 2Bn + Na]⁺, 12), 587.1 ([M - Bn + H]⁺, 23), 609.4 ([M - Bn + Na]⁺, 24), 677.1 ([M + H]⁺, 100), 699.3 ([M + Na]⁺, 49). ¹H NMR (400 MHz, CDCl₃): δ 8.72 (s, 1H, H-2), 8.07 (s, 1H, H-8), 7.44-7.24 (m, 15H, BnH), 7.16 (m, 1H, BnH), 7.03 (m, 2H, BnH), 6.64 (m, 2H, BnH), 5.68 (d, *J* = 9.0 Hz, 1H, H-1'), 5.05 (d, *J* = 11.5 Hz, 1H, Bn-CHH), 4.84 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.79 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.70 (d, *J* = 11.5 Hz, 1H, Bn-CHH), 4.69 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.43 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.32 (dd, *J* = 9.2 Hz, *J* = 9.0 Hz, 1H, H-2'), 4.24 (d, *J* = 14.4 Hz, 1H, Bn-CHH), 4.09 (m, 1H, H-4'), 3.86 (m, 2H, H-5' and H-3'), 3.61-3.59 (m, 2H, H-6'a and H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 152.0 (C-2), 151.6 (C-4), 150.8 (C-6), 143.0 (C-8), 138.3 (Bn-Cq), 137.7 (Bn-Cq), 137.4 (Bn-Cq), 136.4 (Bn-Cq), 131.1 (C-5), 128.6 (Bn), 128.6 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (Bn), 128.3 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.6 (Bn), 127.6 (Bn), 83.4 (C-3'), 82.8 (C-1'), 77.7 (C-2'), 76.6 (C-5'), 75.1 (Bn-CH₂), 74.7 (Bn-CH₂), 73.6 (Bn-CH₂), 73.2 (C-4'), 72.8 (Bn-CH₂), 68.2 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.00; H, 5.77; N, 8.17.

6-Chloro-7-(2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl)purine (10), *6-Chloro-7-(2,3,4,6-tetra-O-benzyl-β-D-*

mannopyranosyl)purine (11), *6-Chloro-9-(2,3,4,6-tetra-O-benzyl- α -D-mannopyranosyl)purine (12)* and *6-Chloro-9-(2,3,4,6-tetra-O-benzyl- β -D-mannopyranosyl)purine (13)*. The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl- α -D-mannopyranoside (250 mg, 0.45 mmol) and CP (104 mg, 0.67 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **10** (52.2 mg; 17 %), **11** (42.8 mg; 14 %), **12** (82.6 mg; 27 %) and **13** (30.6 mg; 10 %). Data for compound **10**: colourless oil; Rf = 0.46 (EtOAc/cyclohexane 1:1). $[\alpha]_D^{20} + 82^\circ$ (c 0.86, CHCl₃). ESI-MS *m/z* (%): 676.9 ([M + H]⁺, 100), 699.3 ([M + Na]⁺, 6). ¹H NMR (400 MHz, CDCl₃): δ 8.87 (s, 1H, H-2), 8.28 (s, 1H, H-8), 7.41-7.12 (m, 18H, BnH), 6.82 (m, 2H, BnH), 6.49 (d, *J* = 9.1 Hz, 1H, H-1'), 4.69 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.62 (d, *J* = 4.3 Hz, 1H, Bn-CHH), 4.59 (d, *J* = 4.3 Hz, 1H, Bn-CHH), 4.50 (s, 2H, Bn-CH₂), 4.44 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.39 (dd, *J* = 6.6 Hz, *J* = 6.6 Hz, 1H, H-5'), 4.28 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.12 (dd, *J* = 9.1 Hz, *J* = 2.8 Hz, 1H, H-2'), 4.06 (dd, *J* = 2.8 Hz, *J* = 2.8 Hz, 1H, H-3'), 4.02 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 3.94 (dd, *J* = 10.3 Hz, *J* = 7.6 Hz, 1H, H-6'a), 3.83 (dd, *J* = 3.5 Hz, *J* = 1.3 Hz, 1H, H-4'), 3.71 (dd, *J* = 10.3 Hz, *J* = 5.9 Hz, 1H, H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 161.6 (C-4), 152.2 (C-2), 146.9 (C-8), 143.4 (C-6), 137.6 (Bn-Cq), 137.4 (Bn-Cq), 137.3 (Bn-Cq), 136.0 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.3 (Bn), 128.2 (Bn), 128.1 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 122.6 (C-5), 78.6 (C-1'), 74.1 (C-3'), 77.1 (C-5'), 75.4 (C-2'), 73.3 (Bn-CH₂), 73.3 (Bn-CH₂), 71.9 (Bn-CH₂), 73.5 (C-4'), 71.3 (Bn-CH₂), 67.5 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 68.96; H, 5.63; N, 8.11.

Data for compound **11**: colourless oil; Rf = 0.31 (EtOAc/hexane 1:1). $[\alpha]_D^{20} + 62^\circ$ (c 1.02, CHCl₃). ESI-MS *m/z* (%): 587.1 ([M - Bn + H]⁺, 100), 609.3 ([M - Bn + Na]⁺, 29), 677.0 ([M + H]⁺, 4). ¹H NMR (400 MHz, CDCl₃): δ 8.77 (s, 1H, H-2), 8.51 (s, 1H, H-8), 7.46-7.23 (m, 15H, BnH), 6.92-6.86 (m, 3H, BnH), 6.73 (m, 2H, BnH), 6.90 (d, *J* = 1.0 Hz, 1H, H-1'), 4.98 (d, *J* = 10.8 Hz, 1H, Bn-CHH), 4.90 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.80 (d, *J* = 11.7 Hz, 1H, Bn-CHH), 4.68 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.66 (d, *J* = 10.8 Hz, 1H, Bn-CHH), 4.64 (d, *J* = 12.4 Hz, 1H, Bn-CHH), 4.56 (d, *J* = 12.4 Hz, 1H, Bn-CHH), 4.07 (dd, *J* = 9.5 Hz, *J* = 9.5 Hz, 1H, H-4'), 4.02 (dd, *J* = 2.5 Hz, *J* = 1.0 Hz, 1H, H-2'), 3.84 (dd, *J* = 9.5 Hz, *J* = 2.5 Hz, 1H, H-3'), 3.78 (m, 2H, H-6'a and H-6'b), 3.71 (ddd, *J* = 9.5 Hz, *J* = 3.6 Hz, *J* = 3.6 Hz, 1H, H-5'), 4.34 (d, *J* = 11.8 Hz, 1H, Bn-CHH). ¹³C NMR (100 MHz, CDCl₃): δ 161.8 (C-4), 151.8 (C-2), 147.9 (C-8), 141.1 (C-6), 137.8 (Bn-Cq), 137.7 (Bn-Cq), 137.4 (Bn-Cq), 135.6 (Bn-Cq), 128.8 (Bn), 128.8 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 120.4 (C-5), 83.9 (C-1'), 82.3 (C-3'), 75.4 (Bn-CH₂), 74.1 (Bn-CH₂), 74.0 (Bn-CH₂), 73.6 (C-5'), 73.5 (Bn-CH₂), 72.8 (C-2'), 73.5 (C-4'), 67.8 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.04; H, 5.62; N, 8.17.

Data for compound **12**: colourless oil; Rf = 0.27 (EtOAc/hexane 1:2). $[\alpha]_D^{20} + 64^\circ$ (c 1.58, CHCl₃). ESI-MS *m/z* (%): 677.0 ([M + H]⁺, 100), 699.1 ([M + Na]⁺, 26), 1354.8 ([2M + 2H]⁺, 23), 1374.9 ([2M + Na]⁺, 18). ¹H NMR (400 MHz, CDCl₃): δ 8.60 (s, 1H, H-2), 8.11 (s, 1H, H-8), 7.39-7.20 (m, 15H, BnH), 7.16 (m, 1H, BnH), 7.09 (m, 2H, BnH), 6.88 (m, 2H, BnH), 6.03 (d, *J* = 8.1 Hz, 1H, H-1'), 4.76 (dd, *J* = 8.1 Hz, *J* = 2.6 Hz, 1H, H-2'), 4.72 (d, *J* = 12.3 Hz, 1H, Bn-CHH), 4.65 (d, *J* = 12.3 Hz, 1H, Bn-CHH), 4.52 (d, *J* = 12.2 Hz, 1H, Bn-CHH), 4.50 - 4.42 (m, 5H, Bn-CH₂ and H-5'), 4.16 (d, *J*

= 12.2 Hz, 1H, Bn-CHH), 3.99 (dd, *J* = 2.8 Hz, *J* = 2.8 Hz, 1H, H-3'), 3.86 (dd, *J* = 5.8 Hz, *J* = 3.2 Hz, 1H, H-4'), 3.75 (dd, *J* = 10.8 Hz, *J* = 6.0 Hz, 1H, H-6'a), 3.65 (dd, *J* = 10.8 Hz, *J* = 3.9 Hz, 1H, H-6'b). ¹³C NMR (100 MHz, CDCl₃): δ 151.7 (C-2), 151.4 (C-4), 150.9 (C-6), 144.9 (C-8), 137.8 (Bn-Cq), 137.6 (Bn-Cq), 137.5 (Bn-Cq), 136.4 (Bn-Cq), 132.0 (C-5), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.3 (Bn), 128.3 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 80.9 (C-1'), 75.8 (C-5'), 74.9 (C-4'), 74.1 (C-3'), 73.2 (Bn-CH₂), 72.8 (Bn-CH₂), 72.7 (Bn-CH₂), 72.1 (C-2'), 71.6 (Bn-CH₂), 68.3 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.00; H, 5.64; N, 7.97.

Data for compound **13**: colourless oil; Rf = 0.24 (EtOAc/hexane 1:2). $[\alpha]_D^{20} + 56^\circ$ (c 0.91, CHCl₃). ESI-MS *m/z* (%): 677.1 ([M + H]⁺, 100), 699.3 ([M + Na]⁺, 38). ¹H NMR (400 MHz, CDCl₃): δ 8.55 (s, 1H, H-2), 8.38 (s, 1H, H-8), 7.43-7.20 (m, 15H, BnH), 7.06-6.98 (m, 3H, BnH), 6.86 (m, 2H, BnH), 5.81 (d, *J* = 1.1 Hz, 1H, H-1'), 4.95 (d, *J* = 10.8 Hz, 1H, Bn-CHH), 4.84 (m, 2H, Bn-CH₂), 4.76 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.65 (d, *J* = 10.8 Hz, 1H, Bn-CHH), 4.62 (d, *J* = 12.3 Hz, 1H, Bn-CHH), 4.56 (d, *J* = 12.3 Hz, 1H, Bn-CHH), 4.33 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.09 (m, 2H, H-2' and H-4'), 3.91 (dd, *J* = 9.4 Hz, *J* = 2.6 Hz, 1H, H-3'), 3.77-3.72 (m, 3H, H-6'a and H-6'b and H-5'). ¹³C NMR (100 MHz, CDCl₃): δ 151.3 (C-2), 150.6 (C-6), 149.8 (C-4), 144.6 (C-8), 137.8 (Bn-Cq), 137.8 (Bn-Cq), 137.6 (Bn-Cq), 136.0 (Bn-Cq), 130.7 (C-5), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.6 (Bn), 127.6 (Bn), 83.1 (C-3'), 82.1 (C-1'), 78.8 (C-5'), 75.5 (Bn-CH₂), 74.1 (C-4'), 74.4 (Bn-CH₂), 73.5 (Bn-CH₂), 73.2 (Bn-CH₂), 72.6 (C-2'), 68.8 (C-6'). Elemental anal. calcd for C₃₉H₃₇ClN₄O₅: C, 69.17; H, 5.51; N, 8.27; Found: C, 69.04; H, 5.76; N, 8.04.

2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)purine (14), *2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- β -D-glucopyranosyl)purine (15)* and *2-(Acetamido)-6-chloro-9-(2,3,4,6-tetra-O-benzyl- β -D-glucopyranosyl)purine (16)*. The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl- α -D-glucopyranoside (39 mg, 0.07 mmol) and ACP (23 mg, 0.11 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **14** (3.6 mg; 7 %), **15** (17.5 mg; 34 %) and **16** (14.9 mg; 29 %). Data for compound **14**: yellow crystals; mp 81-84 °C; Rf = 0.23 (EtOAc/hexane 1:1). $[\alpha]_D^{20} + 33^\circ$ (c 0.88, CHCl₃). ESI-MS *m/z* (%): 734.2 ([M + H]⁺, 100), 756.3 ([M + Na]⁺, 54), 1467.1 ([2M + H]⁺, 34). ¹H NMR (400 MHz, CDCl₃): δ 8.61 (s, 1H, H-8), 8.06 (s, 1H, NH), 7.42-7.24 (m, 12H, BnH), 7.21-7.08 (m, 6H, BnH), 6.96 (m, 2H, BnH), 6.24 (d, *J* = 4.8 Hz, 1H, H-1'), 4.86 (d, *J* = 11.2 Hz, 1H, Bn-CHH), 4.81 (d, *J* = 11.2 Hz, 1H, Bn-CHH), 4.75 (d, *J* = 11.1 Hz, 1H, Bn-CHH), 4.71 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.56 (d, *J* = 11.1 Hz, 1H, Bn-CHH), 4.55 (d, *J* = 12.2 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 12.2 Hz, 1H, Bn-CHH), 4.36 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.09 (dd, *J* = 6.7 Hz, *J* = 4.8 Hz, 1H, H-2'), 4.04 (dd, *J* = 7.4 Hz, *J* = 6.7 Hz, 1H, H-3'), 3.84 (dd, *J* = 9.5 Hz, *J* = 6.7 Hz, 1H, H-4'), 3.66 (dd, *J* = 10.6 Hz, *J* = 3.5 Hz, 1H, H-6'a), 3.56 (m, 2H, H-5' and H-6'b), 2.63 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 167.1 (Ac-COO), 162.8 (C-4), 152.4 (C-2), 149.3 (C-8), 143.6 (C-6), 137.5 (Bn-Cq), 137.5 (Bn-Cq), 137.5 (Bn-Cq), 136.2 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 118.2 (C-5), 81.0 (C-1'), 80.8 (C-3'),

76.9 (C-2'), 76.6 (C-4'), 74.6 (Bn-CH₂), 74.3 (Bn-CH₂), 74.0 (Bn-CH₂), 73.5 (Bn-CH₂), 73.1 (C-5'), 68.0 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for C₄₁H₄₀ClN₅O₆: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.87; H, 5.63; N, 9.32.

Data for compound **15**: yellow crystals; mp 71–74 °C; Rf = 0.09 (EtOAc/hexane 1:1). [α]_D²⁰ – 13° (c 0.99, CHCl₃). ESI-MS *m/z* (%): 734.13 ([M + H]⁺, 100), 756.2 ([M + Na]⁺, 78). ¹H NMR (400 MHz, CDCl₃): δ 8.15 (s, 1H, H-8), 8.06 (s, 1H, NH), 7.39–7.17 (m, 15H, BnH), 7.10–6.99 (m, 3H, BnH), 6.80 (m, 2H, BnH), 5.61 (br, 1H, H-1'), 5.00 (d, *J* = 10.9 Hz, 1H, Bn-CHH), 4.94 (d, *J* = 10.9 Hz, 1H, Bn-CHH), 4.88 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.64 (d, *J* = 11.5 Hz, 1H, Bn-CHH), 4.63 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.54 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.24 (d, *J* = 11.5 Hz, 1H, Bn-CHH), 3.94–3.84 (m, 3H, H-2' and H-3' and H-5'), 3.77–3.67 (m, 3H, H-4' and H-6'a and H-6'b), 2.64 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 167.6 (Ac-COO), 162.8 (C-4), 152.1 (C-2), 149.3 (C-8), 143.6 (C-6), 137.7 (Bn-Cq), 137.5 (Bn-Cq), 136.6 (Bn-Cq), 136.0 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (Bn), 128.3 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 117.9 (C-5), 85.9 (C-1'), 85.9 (C-3'), 78.1 (C-4'), 77.2 (C-2'), 77.2 (C-5'), 75.9 (Bn-CH₂), 75.3 (Bn-CH₂), 74.7 (Bn-CH₂), 73.5 (Bn-CH₂), 68.3 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for C₄₁H₄₀ClN₅O₆: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.81; H, 5.52; N, 9.33.

Data for compound **16**: colourless oil; Rf = 0.53 (EtOAc/hexane 1:1). [α]_D²⁰ – 24° (c 1.01, CHCl₃). ESI-MS *m/z* (%): 734.2 ([M + H]⁺, 88), 756.3 ([M + Na]⁺, 100), 1468.9 ([2M + H]⁺, 28), 1489.7 ([2M + Na]⁺, 10). ¹H NMR (400 MHz, CDCl₃): δ 8.05 (s, 1H, NH), 8.92 (s, 1H, H-8), 7.39–7.18 (m, 15H, BnH), 7.12–6.98 (m, 3H, BnH), 6.71 (m, 2H, BnH), 5.38 (d, *J* = 9.1 Hz, 1H, H-1'), 5.00 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.94 (d, *J* = 11.0 Hz, 1H, Bn-CHH), 4.88 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.64 (d, *J* = 10.7 Hz, 1H, Bn-CHH), 4.61 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.52 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.45 (d, *J* = 12.1 Hz, 1H, Bn-CHH), 4.24 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.11 (dd, *J* = 9.0 Hz, *J* = 9.0 Hz, 1H, H-2'), 3.87 (dd, *J* = 9.0 Hz, *J* = 9.0 Hz, 1H, H-3'), 3.80 (dd, *J* = 9.0 Hz, *J* = 9.0 Hz, 1H, H-4'), 3.75–3.68 (m, 3H, H-6'a and H-6'b and H-5'), 2.50 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 171.1 (Ac-COO), 151.9 (C-2), 151.8 (C-4), 151.2 (C-6), 143.0 (C-8), 137.9 (Bn-Cq), 137.5 (Bn-Cq), 137.5 (Bn-Cq), 136.3 (Bn-Cq), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (C-5), 127.7 (Bn), 127.7 (Bn), 85.9 (C-3'), 83.8 (C-1'), 75.1 (C-2'), 77.9 (C-5'), 77.2 (C-4'), 75.8 (Bn-CH₂), 75.2 (Bn-CH₂), 74.5 (Bn-CH₂), 73.5 (Bn-CH₂), 68.2 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for C₄₁H₄₀ClN₅O₆: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.81; H, 5.70; N, 9.42.

2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- α -D-galactopyranosyl)purine (**17**), 2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- β -D-galactopyranosyl)purine (**18**), 2-(Acetamido)-6-chloro-9-(2,3,4,6-tetra-O-benzyl- α -D-galactopyranosyl)purine (**19**) and 2-(Acetamido)-6-chloro-9-(2,3,4,6-tetra-O-benzyl- β -D-galactopyranosyl)purine (**20**). The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl- α -D-galactopyranoside (600 mg, 1.08 mmol) and ACP (340 mg, 1.62 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane, 1:1) yielded **17** (25.2 mg; 3%), **18** (346.5 mg; 44%), **19** (78.8 mg; 10%) and **20** (322.9 mg; 41%). Data for compound **17**: yellow oil; Rf = 0.11 (EtOAc/heptane 3:2). [α]_D²⁰ + 3° (c 1.00, CHCl₃). ESI-MS *m/z* (%): 734.1 ([M + H]⁺, 100), 756.3 ([M + Na]⁺, 28), 1467.8 ([2M + H]⁺, 58), 1491.1 ([2M + Na]⁺, 28).

¹H NMR (400 MHz, CDCl₃): δ 8.56 (s, 1H, H-8), 8.28 (s, 1H, NH), 7.47–7.22 (m, 15H, BnH), 7.19–7.08 (m, 3H, BnH), 6.86 (m, 2H, BnH), 6.36 (d, *J* = 2.4 Hz, 1H, H-1'), 4.84 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.75 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.70 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.67 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.55 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.50 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.28–4.20 (m, 2H, H-5' and H-4'), 4.14 (d, *J* = 11.9 Hz, 1H, Bn-CHH), 4.01–3.95 (m, 3H, H-3' and H-6'a and H-2'), 3.81 (dd, *J* = 11.4 Hz, *J* = 3.5 Hz, 1H, H-6'b), 2.67 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 171.6 (Ac-COO), 162.8 (C-4), 152.1 (C-2), 149.2 (C-8), 142.6 (C-6), 137.7 (Bn-Cq), 137.6 (Bn-Cq), 137.5 (Bn-Cq), 135.9 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.3 (Bn), 128.3 (Bn), 128.3 (Bn), 128.3 (Bn), 128.2 (Bn), 128.1 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 117.7 (C-5), 78.5 (C-1'), 75.1 (C-5'), 74.7 (C-3'), 74.4 (C-2'), 73.4 (Bn-CH₂), 73.3 (Bn-CH₂), 73.1 (Bn-CH₂), 73.0 (Bn-CH₂), 72.5 (C-4'), 65.5 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for C₄₁H₄₀ClN₅O₆: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.77; H, 5.53; N, 9.39.

Data for compound **18**: yellow oil; Rf = 0.26 (EtOAc/cyclohexane 1:1). [α]_D²⁰ – 4° (c 1.26, CHCl₃). ESI-MS *m/z* (%): 734.2 ([M + H]⁺, 82), 756.4 ([M + Na]⁺, 22), 1468.9 ([2M + H]⁺, 100), 1491.2 ([2M + Na]⁺, 76). ¹H NMR (400 MHz, CDCl₃): δ 8.16 (s, 1H, H-8), 8.00 (s, 1H, NH), 7.43–7.23 (m, 15H, BnH), 7.12–7.01 (m, 3H, BnH), 6.81 (m, 2H, BnH), 5.65 (d, *J* = 7.3 Hz, 1H, H-1'), 5.00 (d, *J* = 11.2 Hz, 1H, Bn-CHH), 4.84 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.77 (d, *J* = 11.6 Hz, 1H, Bn-CHH), 4.71 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.62 (d, *J* = 11.2 Hz, 1H, Bn-CHH), 4.48 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.43 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.29 (d, *J* = 11.4 Hz, 1H, Bn-CHH), 4.28 (m, 1H, H-2'), 4.09 (d, *J* = 2.5 Hz, 1H, H-4'), 3.84 (m, 1H, H-5'), 3.79 (dd, *J* = 9.3 Hz, *J* = 2.5 Hz, 1H, H-3'), 3.66–3.57 (m, 2H, H-6'a and H-6'b), 2.63 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 171.4 (Ac-COO), 162.9 (C-4), 152.0 (C-2), 147.9 (C-8), 143.7 (C-6), 138.1 (Bn-Cq), 137.5 (Bn-Cq), 137.3 (Bn-Cq), 136.0 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.6 (Bn), 127.6 (Bn), 118.7 (C-5), 85.2 (C-1'), 83.6 (C-3'), 77.2 (C-2'), 76.5 (C-5'), 75.1 (Bn-CH₂), 75.0 (Bn-CH₂), 73.6 (Bn-CH₂), 73.2 (C-4'), 72.6 (Bn-CH₂), 68.2 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for C₄₁H₄₀ClN₅O₆: C, 67.07; H, 5.49; N, 9.54; Found: C, 67.00; H, 5.67; N, 9.40.

Data for compound **19**: yellow oil; Rf = 0.56 (EtOAc/heptane 3:2). [α]_D²⁰ + 5° (c 0.99, CHCl₃). ESI-MS *m/z* (%): 734.1 ([M + H]⁺, 100), 756.4 ([M + Na]⁺, 54), 1467.5 ([2M + H]⁺, 38), 1492.1 ([2M + Na]⁺, 22). ¹H NMR (400 MHz, CDCl₃): δ 8.25 (s, 1H, H-8), 8.04 (s, 1H, NH), 7.47–7.12 (m, 18H, BnH), 6.89 (m, 2H, BnH), 6.08 (d, *J* = 3.0 Hz, 1H, H-1'), 4.86 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.77 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.71 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.68 (d, *J* = 11.8 Hz, 1H, Bn-CHH), 4.53 (m, 2H, Bn-CH₂), 4.52 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.44–4.28 (m, 2H, H-5' and H-4'), 4.20 (d, *J* = 12.0 Hz, 1H, Bn-CHH), 4.15 (m, 1H, H-3'), 4.03 (dd, *J* = 11.2 Hz, *J* = 8.3 Hz, 1H, H-6'a), 3.97 (m, 1H, H-2'), 3.81 (dd, *J* = 11.2 Hz, *J* = 3.4 Hz, 1H, H-6'b), 2.44 (s, 3H, Ac-Me). ¹³C NMR (100 MHz, CDCl₃): δ 171.5 (Ac-COO), 152.2 (C-2), 151.5 (C-4), 150.9 (C-6), 144.3 (C-8), 137.8 (Bn-Cq), 137.7 (Bn-Cq), 137.7 (Bn-Cq), 136.2 (Bn-Cq), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.3 (Bn), 128.3 (Bn), 128.2 (Bn), 128.2 (Bn), 128.2 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.8 (C-5), 127.7 (Bn), 127.6 (Bn), 77.1 (C-1'), 75.4 (C-5'), 74.7 (C-3'), 74.1 (C-2'), 73.3 (Bn-CH₂), 73.2 (Bn-CH₂), 73.1 (Bn-CH₂), 73.0 (Bn-CH₂), 72.9 (C-4'), 65.9 (C-

6'), 25.1 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 69.80; H, 5.69; N, 9.41.

Data for compound **20**: a colourless oil; Rf = 0.57 (EtOAc/hexane 1:1). $[\alpha]_D^{20} - 14^\circ$ (c 1.02, $CHCl_3$). ESI-MS m/z (%): 734.3 ($[M + H]^+$, 100), 756.5 ($[M + Na]^+$, 56), 1467.9 ($[2M + H]^+$, 22). 1H NMR (400 MHz, $CDCl_3$): δ 7.93 (s, 1H, NH), 7.92 (s, 1H, H-8), 7.43-7.22 (m, 15H, BnH), 7.10 (m, 1H, BnH), 7.01 (m, 2H, BnH), 6.73 (m, 2H, BnH), 5.35 (d, $J = 9.0$ Hz, 1H, H-1'), 4.96 (d, $J = 11.4$ Hz, 1H, Bn-CHH), 4.81 (d, $J = 11.7$ Hz, 1H, Bn-CHH), 4.75 (d, $J = 11.7$ Hz, 1H, Bn-CHH), 4.68 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 4.64 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 4.45 (d, $J = 11.9$ Hz, 1H, Bn-CHH), 4.43 (m, 1H, H-2'), 4.40 (d, $J = 11.9$ Hz, 1H, Bn-CHH), 4.29 (d, $J = 11.4$ Hz, 1H, Bn-CHH), 4.06 (m, 1H, H-4'), 3.79 (dd, $J = 6.3$ Hz, $J = 6.3$ Hz, 1H, H-5'), 3.76 (dd, $J = 9.6$ Hz, $J = 2.6$ Hz, 1H, H-3'), 3.55 (m, 2H, H-6'a and H-6'b), 2.42 (s, 3H, Ac-Me). ^{13}C NMR (100 MHz, $CDCl_3$): δ 171.3 (Ac-COO), 152.1 (C-2), 151.9 (C-4), 151.1 (C-6), 143.1 (C-8), 138.2 (Bn-Cq), 137.6 (Bn-Cq), 137.4 (Bn-Cq), 136.6 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.1 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 127.8 (C-5), 127.6 (Bn), 127.6 (Bn), 83.9 (C-1'), 83.6 (C-3'), 76.5 (C-5'), 75.7 (C-2'), 74.8 (Bn-CH₂), 74.8 (Bn-CH₂), 73.6 (Bn-CH₂), 73.0 (C-4'), 72.6 (Bn-CH₂), 68.2 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.92; H, 5.61; N, 9.47.

2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- α -D-mannopyranosyl)purine (**21**), 2-(Acetamido)-6-chloro-7-(2,3,4,6-tetra-O-benzyl- β -D-mannopyranosyl)purine (**22**), 2-(Acetamido)-6-chloro-9-(2,3,4,6-tetra-O-benzyl- α -D-mannopyranosyl)purine (**23**) and 2-(Acetamido)-6-chloro-9-(2,3,4,6-tetra-O-benzyl- β -D-mannopyranosyl)purine (**24**). The compounds were obtained by the reaction of methyl 2,3,4,6-tetra-O-benzyl- α -D-mannopyranoside (250 mg, 0.45 mmol) and ACP (112 mg, 0.54 mmol) according to the general procedure. Purification by column chromatography (EtOAc/cyclohexane 1:1) yielded **21** (27.1 mg; 8 %), **22** (92.5 mg; 28 %), **23** (81.3 mg; 24 %) and **24** (10.2 mg, 3 %). Data for compound **21**: yellow oil; Rf = 0.47 (EtOAc/hexane 4:1). $[\alpha]_D^{20} + 38^\circ$ (c 1.03, $CHCl_3$). ESI-MS m/z (%): 734.1 ($[M + H]^+$, 100), 756.3 ($[M + Na]^+$, 58), 1467.9 ($[2M + H]^+$, 20), 1488.7 ($[2M + Na]^+$, 8). 1H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H, H-8), 8.02 (s, 1H, NH), 7.41-7.14 (m, 18H, BnH), 6.88 (m, 2H, BnH), 6.36 (d, $J = 8.9$ Hz, 1H, H-1'), 4.68 (d, $J = 12.0$ Hz, 1H, Bn-CHH), 4.60 (d, $J = 12.0$ Hz, 1H, Bn-CHH), 4.59 (d, $J = 11.6$ Hz, 1H, Bn-CHH), 4.50 (s, 2H, Bn-CH₂), 4.44 (d, $J = 11.6$ Hz, 1H, Bn-CHH), 4.37 (m, 1H, H-5'), 4.30 (d, $J = 11.9$ Hz, 1H, Bn-CHH), 4.11 (dd, $J = 8.9$ Hz, $J = 2.5$ Hz, 1H, H-2'), 4.05 (m, 1H, H-3'), 4.04 (d, $J = 11.9$ Hz, 1H, Bn-CHH), 3.92 (dd, $J = 10.2$ Hz, $J = 7.5$ Hz, 1H, H-6'a), 3.82 (dd, $J = 3.3$ Hz, $J = 1.2$ Hz, 1H, H-4'), 3.69 (dd, $J = 10.2$ Hz, $J = 5.9$ Hz, 1H, H-6'b), 2.63 (s, 3H, Ac-Me). ^{13}C NMR (100 MHz, $CDCl_3$): δ 171.5 (Ac-COO), 162.9 (C-4), 152.1 (C-2), 147.6 (C-8), 143.8 (C-6), 137.6 (Bn-Cq), 137.4 (Bn-Cq), 137.3 (Bn-Cq), 136.1 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 127.9 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 119.1 (C-5), 78.6 (C-1'), 77.2 (C-5'), 75.1 (C-2'), 74.1 (C-4'), 73.5 (C-3'), 73.3 (Bn-CH₂), 73.3 (Bn-CH₂), 71.9 (Bn-CH₂), 71.3 (Bn-CH₂), 67.4 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.82; H, 5.54; N, 9.31.

Data for compound **22**: yellow crystals; mp 80-82 °C; Rf = 0.36 (EtOAc/hexane 4:1). $[\alpha]_D^{20} + 74^\circ$ (c 0.98, $CHCl_3$). ESI-MS m/z (%): 734.5 ($[M + H]^+$, 70), 756.5 ($[M + Na]^+$, 20), 1469.2 ($[2M + H]^+$, 100), 1491.3 ($[2M + Na]^+$, 44). 1H NMR (400 MHz, $CDCl_3$): δ 8.34

(s, 1H, H-8), 8.09 (s, 1H, NH), 7.38-7.16 (m, 15H, BnH), 6.89 (m, 3H, BnH), 6.71 (m, 2H, BnH), 5.75 (d, $J = 1.0$ Hz, 1H, H-1'), 4.90 (d, $J = 10.9$ Hz, 1H, Bn-CHH), 4.83 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 4.72 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 4.61 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 4.59 (d, $J = 10.9$ Hz, 1H, Bn-CHH), 4.55 (d, $J = 12.4$ Hz, 1H, Bn-CHH), 4.49 (d, $J = 12.4$ Hz, 1H, Bn-CHH), 4.26 (d, $J = 11.8$ Hz, 1H, Bn-CHH), 3.98 (dd, $J = 9.4$ Hz, $J = 9.4$ Hz, 1H, H-4'), 3.91 (m, 1H, H-2'), 3.75 (dd, $J = 9.4$ Hz, $J = 2.5$ Hz, 1H, H-3'), 3.71 (m, 3H, H-6'a and H-6'b and H-5'), 2.56 (s, 3H, Ac-Me). ^{13}C NMR (100 MHz, $CDCl_3$): δ 172.2 (Ac-COO), 162.9 (C-4), 152.9 (C-2), 148.5 (C-8), 141.5 (C-6), 137.7 (Bn-Cq), 137.7 (Bn-Cq), 137.4 (Bn-Cq), 135.8 (Bn-Cq), 128.8 (Bn), 128.8 (Bn), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.2 (Bn), 128.2 (Bn), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.8 (Bn), 127.8 (Bn), 127.8 (Bn), 127.6 (Bn), 116.9 (C-5), 83.9 (C-1'), 82.3 (C-3'), 78.9 (C-5'), 74.0 (C-4'), 75.2 (Bn-CH₂), 74.2 (Bn-CH₂), 73.7 (Bn-CH₂), 73.4 (Bn-CH₂), 72.9 (C-2'), 68.7 (C-6'), 25.2 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.87; H, 5.39; N, 9.47.

Data for compound **23**: yellow oil; Rf = 0.73 (EtOAc/hexane 1:1). $[\alpha]_D^{20} + 50^\circ$ (c 1.22, $CHCl_3$). ESI-MS m/z (%): 734.5 ($[M + H]^+$, 100), 756.5 ($[M + Na]^+$, 47), 1467.1 ($[2M + H]^+$, 24), 1491.1 ($[2M + Na]^+$, 34). 1H NMR (400 MHz, $CDCl_3$): δ 7.94 (s, 1H, H-8), 7.94 (s, 1H, NH), 7.37-7.00 (m, 18H, BnH), 6.82 (m, 2H, BnH), 5.85 (d, $J = 8.6$ Hz, 1H, H-1'), 4.68 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.65 (m, 1H, H-2'), 4.62 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.48 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 4.43 (d, $J = 12.6$ Hz, 1H, Bn-CHH), 4.42 (br, 2H, Bn-CH₂), 4.40 (m, 1H, H-5'), 4.40 (d, $J = 12.6$ Hz, 1H, Bn-CHH), 4.10 (d, $J = 12.1$ Hz, 1H, Bn-CHH), 3.96 (dd, $J = 2.7$ Hz, $J = 2.7$ Hz, 1H, H-3'), 3.70 (dd, $J = 10.7$ Hz, $J = 6.3$ Hz, 1H, H-6'a), 3.80 (dd, $J = 5.2$ Hz, $J = 2.9$ Hz, 1H, H-4'), 3.59 (dd, $J = 10.6$ Hz, $J = 4.2$ Hz, 1H, H-6'b), 2.34 (s, 3H, Ac-Me). ^{13}C NMR (100 MHz, $CDCl_3$): δ 170.5 (Ac-COO), 152.1 (C-2), 151.5 (C-4), 151.2 (C-6), 144.5 (C-8), 137.8 (Bn-Cq), 137.5 (Bn-Cq), 137.3 (Bn-Cq), 136.5 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (Bn), 128.2 (Bn), 128.2 (Bn), 128.2 (C-5), 128.1 (Bn), 128.1 (Bn), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.7 (Bn), 127.6 (Bn), 127.6 (Bn), 80.7 (C-1'), 76.0 (C-5'), 74.7 (C-4'), 73.6 (C-3'), 73.1 (C-2'), 72.7 (Bn-CH₂), 72.1 (Bn-CH₂), 71.9 (Bn-CH₂), 71.2 (Bn-CH₂), 68.1 (C-6'), 25.1 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.91; H, 5.52; N, 9.41.

Data for compound **24**: yellow oil; Rf = 0.61 (EtOAc/hexane 1:1). $[\alpha]_D^{20} + 77^\circ$ (c 1.00, $CHCl_3$). ESI-MS m/z (%): 734.5 ($[M + H]^+$, 100), 756.6 ($[M + Na]^+$, 52). 1H NMR (400 MHz, $CDCl_3$): δ 8.21 (s, 1H, H-8), 8.19 (s, 1H, NH), 7.38-7.16 (m, 15H, BnH), 7.03-6.96 (m, 3H, BnH), 6.83 (m, 2H, BnH), 5.62 (br, 1H, H-1'), 4.89 (d, $J = 10.8$ Hz, 1H, Bn-CHH), 4.79 (m, 2H, Bn-CH₂), 4.72 (d, $J = 11.6$ Hz, 1H, Bn-CHH), 4.59 (d, $J = 10.8$ Hz, 1H, Bn-CHH), 4.56 (d, $J = 12.2$ Hz, 1H, Bn-CHH), 4.49 (d, $J = 12.2$ Hz, 1H, Bn-CHH), 4.32 (d, $J = 11.6$ Hz, 1H, Bn-CHH), 4.05 (m, 1H, H-2'), 4.02 (dd, $J = 9.5$ Hz, $J = 9.5$ Hz, 1H, H-4'), 3.84 (dd, $J = 9.4$ Hz, $J = 2.5$ Hz, 1H, H-3'), 3.72-3.64 (m, 3H, H-6'a and H-6'b and H-5'), 2.38 (s, 3H, Ac-Me). ^{13}C NMR (100 MHz, $CDCl_3$): δ 170.4 (Ac-COO), 151.3 (C-4), 150.8 (C-2), 150.6 (C-6), 143.9 (C-8), 137.8 (Bn-Cq), 137.8 (Bn-Cq), 137.6 (Bn-Cq), 136.2 (Bn-Cq), 128.6 (Bn), 128.6 (Bn), 128.5 (Bn), 128.5 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.4 (Bn), 128.3 (C-5), 128.0 (Bn), 128.0 (Bn), 128.0 (Bn), 127.9 (Bn), 127.9 (Bn), 127.8 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 127.7 (Bn), 82.8 (C-3'), 82.1 (C-1'), 78.7 (C-5'), 75.3 (Bn-CH₂), 74.3 (Bn-CH₂), 74.1 (C-4'), 73.4 (Bn-CH₂), 73.1 (Bn-CH₂), 72.5 (C-2'), 68.7 (C-6'), 25.0 (Ac-Me). Elemental anal. calcd for $C_{41}H_{40}ClN_5O_6$: C, 67.07; H, 5.49; N, 9.54; Found: C, 66.98; H, 5.54; N, 9.37.

Enzymatic Studies

Spectrophotometer and Chemicals. A TECAN SpectraFluorPlus working on the kinetic mode and measuring the absorbance at 415 nm was used for the enzymatic studies. Acetylcholinesterase (from *electrophorus electricus*), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) and acetylthiocholine iodide were purchased from Fluka. Butyrylcholinesterase (from equine serum) was purchased from Sigma and butyrylthiocholine iodide was bought from Aldrich.

Solutions Preparation. Preparation of 50 mM Tris-HCl buffer pH 8.0: Tris(hydroxymethyl)-aminomethan (606 mg) was dissolved in bidistilled water (100 mL) and adjusted with HCl to a pH of 8.0 ± 0.1 . Buffer was freshly prepared and stored in the refrigerator. AChE solution 2.005 U/mL: the enzyme (271 U/mg, 0.037 mg) was dissolved in freshly prepared buffer pH 8.0 (5 mL) containing NaN_3 (0.98 mg). BChE solution 2.040 U/mL: the enzyme (7.54 U/mg, 1.353 mg) was dissolved in freshly prepared buffer pH 8.0 (5 mL) containing NaN_3 (0.98 mg). DTNB solution 3 mM: DTNB (23.8 mg) was dissolved in freshly prepared buffer pH 8.0 (20 mL) containing NaCl (116.8 mg) and MgCl_2 (38.0 mg). ATChI solution 15 mM: ATChI (43.4 mg) was dissolved in bidistilled water (10 mL). BTChI solution 15 mM: BTChI (47.6 mg) was dissolved in bidistilled water (10 mL). All solutions were stored in eppendorf caps in the refrigerator or freezer, if necessary. The pure compounds were initially dissolved in DMSO, galantamine hydrobromide as standard was dissolved in bidistilled water. The final concentrations for the enzymatic assay were yielded by diluting the stock solution with bidistilled water. No inhibition was detected by residual DMSO (<0.5 %).

Enzyme Assay. A mixture of the DTNB solution (125 μL), enzyme (25 μL) and compounds solutions (25 μL , 3 different concentrations and once blank water) was prepared and incubated at 30 °C for 20 min. The substrate (25 μL , 4 different concentrations) was added to start the enzymatic reaction. The absorbance data (415 nm) was recorded under a controlled temperature of 30 °C for 30 min at 1 min intervals. All measurements were performed as triplicates. The final concentrations in the test were as follows: [AChE] = 2.005 U/mL, [BChE] = 2.040 U/mL, [DTNB] = 3 mM, [ATChI] = [BTChI] = 0.9375 mM, 0.625 mM, 0.325 mM, 0.1875 mM. The mode of inhibition as well as K_i and K_i' were determined using Lineweaver-Burk plot³³, Dixon plot³⁴ and Cornish-Bowden plot³⁵.

Conclusions

A series of 24 new nucleosides were synthesized and tested, leading to new insights into the structural features required for BChE or AChE selective inhibition. Selectivity for both these enzymes can be tuned by the purine base, the anomeric configuration and the glycosyl moiety. The 6-chloropurine nucleosides are mainly AChE selective inhibitors, with the exception of their mannosyl nucleosides, which also inhibit BChE. The most potent and selective BChE inhibitors embody the 2-acetamido-6-chloropurine base N⁷-linked to the mannosyl and the glucosyl moieties, and the α -anomers are the most promising isomers, exhibiting activities ranging from K_i 50 nM to 2.46 μM . When compared to the purine bicyclic nucleosides previously designed by us, this new series of compounds is by far much more easy to synthesize, and includes the 2-acetamido-N⁷- α -D-mannosylpurine **21**, a competitive and selective 50 nM BChE inhibitor. This new lead and its BChE selective inhibitor analogs represent new molecular entities that may be useful

for the understanding of BChE's role in AD with potential to further contribute to new therapeutic approaches for AD treatment.

Acknowledgements

The authors wish to thank Dr. Nuno M. Xavier and the Erasmus student Laure Mathon-Claudon for support in the compounds' synthesis. Fundação para a Ciência e a Tecnologia is gratefully acknowledged for Stefan Schwarz Postdoc research grant SFRH/BPD/81065/2011 and the support of the project Pest-OE/QUI/UI0612/2013. The ESI-MS spectra were generously measured by Dr. Ralph Kluge.

Notes and references

- ^a Centro de Química e Bioquímica/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Ed. C8, Piso 5, 1749-016 Lisboa, Portugal; email: aprauter@fc.ul.pt
- ^b Bereich Organische Chemie, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 2, D-06120 Halle (Saale), Germany
- Electronic Supplementary Information (ESI) available: [NMR spectra for compounds **1-24**]. See DOI: 10.1039/b000000x/
- 1 A. Alzheimer, *Allg. Zschr. Psychiatr. Psych. gerichtl. Med.*, 1907, **64**, 146.
 - 2 P. J. Whitehouse, D. L. Price, A. W. Clark, J. T. Coyle and M. R. DeLong, *Ann. Neurol.*, 1981, **10**, 122.
 - 3 R. T. Bartus, R. L. I. Dean, B. Beer and A. S. Lippa, *Science*, 1982, **217**, 408.
 - 4 J. T. Coyle, D. L. Price and M. R. DeLong, *Science*, 1983, **219**, 1184.
 - 5 N. H. Greig, T. Utsuki, Q.-S. Yu, X. Zhu, H. W. Holloway, T. Perry, B. Lee, D. K. Ingram and D. K. Lahiri, *Curr. Med. Res. Opin.*, 2001, **17**, 159.
 - 6 E. Giacobini, in *Morphological and Biochemical Correlates of Neural Activity*, ed. M. M. Cohen and R. S. Snyder, Harper and Row, New York, 1964, pp. 15-38.
 - 7 N. H. Greig, T. Utsuki, D. K. Ingram, Y. Wang, G. Pepeu, C. Scali, Q.-S. Yu, J. Mamczarz, H. W. Holloway, T. Giordano, D. Chen, K. Furukawa, K. Sambamurti, A. Bossi and D. K. Lahiri, *Proc. Natl. Acad. Sci.*, 2005, **102**, 17213.
 - 8 E. Giacobini, in *Cholinesterases and Cholinesterase Inhibitors*, ed. E. Giacobini, Martin Dunitz, London, 2000, pp. 181-226.
 - 9 M.-M. Mesulam, A. Guillozet, P. Shaw, A. Levey, E. G. Duysen and O. Lockridge, *Neurosci.*, 2002, **110**, 627.
 - 10 E. K. Perry, B. E. Tomlinson, G. Blessed, K. Bergmann, P. H. Gibson and R. H. Perry, *Br. Med. J.*, 1978, **2**, 1457.
 - 11 E. Giacobini, *Int. J. Geriatr. Psychiatry*, 2003, **18**, 1.
 - 12 V. Zarotsky, J. J. Sramek and N. R. Cutler, *Am. J. Health Syst. Pharm.*, 2003, **60**, 446.
 - 13 H. Sugimoto, *Pure Appl. Chem.*, 1999, **71**, 2031.
 - 14 H. Sugimoto, Y. Yamanishi, Y. Iimura and Y. Kawakami, *Curr. Med. Chem.*, 2000, **7**, 303.
 - 15 M. W. Jann, *Pharmacotherapy*, 2000, **20**, 1.
 - 16 T. Darreh-Shori, S. Vijayaraghavan, S. Aeinehband, F. Piehlf, R. P. F. Lindblom, B. Nilsson, K. N. Ekdahl, B. Långström, O. Almkvist and A. Nordberg, *Neurobiol. Aging*, 2013, **34**, 2465.

- 17 R. León, A. G. Garcia and J. Marco-Contelles, *Med. Res. Rev.*, 2013, **33**, 139.
- 18 S. Darvesh, M. K. Cash, G. A. Reid, E. Martin, A. Mitnitski and C. Geula, *J. Neuropathol. Exp. Neurol.*, 2012, **71**, 2.
- 19 R. M. Lane and Y. He, *Alzheimers Dement.*, 2013, **9**, 1.
- 20 J. Takahashi, I. Hijikuro, T. Kihara, M. G. Muruges, S. Fuse, R. Kunimoto, Y. Tsumura, A. Akaike, T. Niidome, Y. Okuno, T. Takahashi and H. Sugimoto, *Bioorg. Med. Chem.*, 2010, **20**, 1718.
- 21 Y. J. Woo, B. H. Lee, G. H. Yeun, H. J. Kim, M.-H. Won, S. H. Kim, B. H. Lee, and J. H. Park, *Bull. Korean Chem. Soc.*, 2011, **32**, 2593.
- 22 X. Chen, I. G. Tikhonova and M. Decker, *Bioorg. Med. Chem.*, 2011, **19**, 1222.
- 23 C. Ducho, C. Ducho, U. Görbig, R. Esnouf and J. Balzarini, *J. Med. Chem.*, 2004, **47**, 2839.
- 24 C. Ducho, U. Görbig, S. Jessel, N. Gisch, J. Balzarini and C. Meier, *J. Med. Chem.*, 2007, **50**, 1335.
- 25 F. Marcelo, F. V. M. Silva, M. Goulart, J. Justino, P. Sinaÿ, Y. Blériot and A. P. Rauter, *Bioorg. Med. Chem.*, 2009, **17**, 5106.
- 26 R. N. Shah, J. Baptista, G. R. Perdomo, J. P. Carver and J. J. Krepsinsky, *J. Carbohydr. Chem.*, 1987, **6**, 645.
- 27 P. Garner, J. U. Yoo and R. Sarabu, *Tetrahedron*, 1992, **48**, 4259.
- 28 P. Garner and S. Ramakanth, *J. Org. Chem.*, 1988, **53**, 1294.
- 29 P. I. Pradeepkumar, P. Cheruku, O. Plashkevych, P. Acharya, S. Gohil and J. Chattopadhyaya, *J. Am. Chem. Soc.*, 2004, **126**, 11484.
- 30 M. J. Robins, Z. Guo and S. F. Wnuk, *J. Am. Chem. Soc.*, 1997, **119**, 3637.
- 31 Z.-G. Gao, S.-K. Kim, T. Biadatti, W. Chen, K. Lee, D. Barak, S. G. Kim, C. R. Johnson and K. A. Jacobson, *J. Med. Chem.*, 2002, **45**, 4471.
- 32 S. Di Giovanni, A. Borloz, A. Urbain, A. Marston, K. Hostettmann, P. A. Carrupt, M. Reist, *Eur. J. Pharm. Sci.*, 2008, **33**, 109.
- 33 H. Lineweaver and D. Burk, *J. Am. Chem. Soc.*, 1934, **56**, 658.
- 34 M. Dixon, *Biochem. J.*, 1953, **55**, 170.
- 35 A. Cornish-Bowden, *Biochem. J.*, 1974, **137**, 143.